You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. A novel PEDF peptide mimetic for diabetic retinopathy

    SBC: Skyran Biologics, Inc.            Topic: NEI

    AbstractThe overall goal of Skyran Biologics is to develop a powerful topical therapeutic to combat diabetic retinopathyDRa leading cause of vision loss and total blindness globallyOur research team was one of the first to show that a novel proteinPigment Epithelium Derived FactorPEDFis expressed in the eye and provides significant protection to the injured retinaAfter identifying amer bioactive r ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Automated Object Contouring Methods and Software for Radiotherapy Planning

    SBC: Quantitative Radiology Solutions LLC            Topic: 102

    Abstract In 2015, 1,658,370 new cancer cases are estimated to occur in the US, where nearly two-thirds will have radiation therapy (RT). Given that there are over 2,300 RT centers in the US, and current systems for contouring organs at risk (OARs) rely mostly on manual methods, there is a strong commercial opportunity for producing a software system that can contour OARs in medical images at a hig ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDCD

    Principal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Catheter Based Cardiovascular Device Retrieval System

    SBC: Onocor LLC            Topic: NHLBI

    During the past decade there has been an exponential growth in the numberscope and complexity of catheter based interventions for structural heart diseaseTranscatheter aortic valve replacementTAVRendovascular aneurysm repairEVARvena caval filters and intracardiac defect closure are all well developed and growing treatment strategiesThe recent FDA approval of left atrial appendageLAAocclusion for a ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Commercialization of a Rapid Blood Test for Traumatic Brain Injury

    SBC: Fawkes Biotechnology, LLC            Topic: 100

    Traumatic brain injuryTBIis a substantial health care issue affecting both civilian and military populationsAlthough extremes of head injury are recognizablemild to moderate TBImmTBIis more difficult to diagnose leading to a need for the identification of circulating biomarkers of brain injury that may facilitate early identificationUsing a rat model of TBI we identified a novel marker of neuronal ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Development of GPER agonists as Cancer Therapeutics

    SBC: Linnaeus Therapeutics LLC            Topic: 102

    Project summaryThis project is designed to evaluate a new class of anti cancer agents for treatment of invasive melanomapancreaslungand colon carcinomasThe study compounds are smallsynthetic molecules that have not previously been used in peopleand bind to a surface receptor on tumor cells that has not previously been targeted in cancerStrong preliminary results indicate that the study compounds p ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of Small Molecule Therapeutics Targeting Hemorrhagic Fever Viruses

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    The ultimate goal of this Phase I application is to develop novel small moleculebroad spectrum therapeutics against viral infections caused by filoviruses that depend on the PPxY L domain motif for virus egress and spread of infectionEbolaEBOVand MarburgMARVviruses are highly pathogenic and classified as Category Ahigh priority bioterror pathogensAs there are no commercially available therapeutic ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Dual Tack Mesh Fixation System: Creation of a Mesh Fixation System for Hernia Treatment and Prevention

    SBC: Paradigm Surgical LLC            Topic: 300

    Contact PD PIFischerJohn Dual Tack Mesh Fixation SystemCreation of a Mesh Fixation System for Hernia Treatment and PreventionIncisional herniaIHis a significant public health issue in the United StatesUSwith an estimatedcases per year and over $billion spent on hernia treatmentRecurrence rates for surgical IH repairs areand those who experience recurrence are susceptible to a vicious cycle of morb ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Evaluating Synthetic Biology Produced Triterpene Oils in Adjuvant Formulations

    SBC: Enepret Incorporated            Topic: NIAID

    ABSTRACT Vaccine adjuvants help stimulate the body to generate an immune response when co injected with an antigenthe compound for which immunity is desiredAlthough the human body is capable of producing antibodies to most injected antigensadjuvants can help boost the body s ability to mount a successful and acquired immune response to the presented targetAdjuvants have been shown to enhance immun ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Graft-protective properties of LGM2605 in Lung Transplantation

    SBC: Lignamed, LLC            Topic: NHLBI

    LignaMedLLC is developing LGMa novel medical device that will be administered via an FDA approved ex vivo lung perfusion deviceEVLPto improve lung function parameters of ex vivo donor lungs in advance of transplant surgeryPer FDA device regulations LGMwill be fully flushed and cleared from the donor lung prior to transplantThe major challenge with lung transplantation is the oxidative damage that ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government